Last reviewed · How we verify

Pyridostigmine, Tacrolimus

Da, Yuwei, M.D. · Phase 2 active Small molecule

Pyridostigmine, Tacrolimus is a Small molecule drug developed by Da, Yuwei, M.D.. It is currently in Phase 2 development. Also known as: Pyridostigmine Bromide, Prograf/FK506.

At a glance

Generic namePyridostigmine, Tacrolimus
Also known asPyridostigmine Bromide, Prograf/FK506
SponsorDa, Yuwei, M.D.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pyridostigmine, Tacrolimus

What is Pyridostigmine, Tacrolimus?

Pyridostigmine, Tacrolimus is a Small molecule drug developed by Da, Yuwei, M.D..

Who makes Pyridostigmine, Tacrolimus?

Pyridostigmine, Tacrolimus is developed by Da, Yuwei, M.D. (see full Da, Yuwei, M.D. pipeline at /company/da-yuwei-m-d).

Is Pyridostigmine, Tacrolimus also known as anything else?

Pyridostigmine, Tacrolimus is also known as Pyridostigmine Bromide, Prograf/FK506.

What development phase is Pyridostigmine, Tacrolimus in?

Pyridostigmine, Tacrolimus is in Phase 2.

Related